AU2001237379A1 - Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction - Google Patents

Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction

Info

Publication number
AU2001237379A1
AU2001237379A1 AU2001237379A AU2001237379A AU2001237379A1 AU 2001237379 A1 AU2001237379 A1 AU 2001237379A1 AU 2001237379 A AU2001237379 A AU 2001237379A AU 2001237379 A AU2001237379 A AU 2001237379A AU 2001237379 A1 AU2001237379 A1 AU 2001237379A1
Authority
AU
Australia
Prior art keywords
benzothieno
pde
pyrimidines
treatment
inhibitory effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001237379A
Other versions
AU2001237379B2 (en
Inventor
Marian Brandle
Thomas Ehring
Claudia Wilm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10010612A external-priority patent/DE10010612A1/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2001237379A1 publication Critical patent/AU2001237379A1/en
Application granted granted Critical
Publication of AU2001237379B2 publication Critical patent/AU2001237379B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2001237379A 2000-03-03 2001-02-13 Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction Ceased AU2001237379B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10010612A DE10010612A1 (en) 2000-03-03 2000-03-03 Treatment of erectile dysfunction without inducing circulatory side-effects, using penis-specific phosphodiesterase V inhibitors, preferably benzo (4,5) thieno (2,3-d) pyrimidine derivatives
DE10010612.9 2000-03-03
PCT/EP2001/001557 WO2001064192A2 (en) 2000-03-03 2001-02-13 Use of benzothieno-2,3-d-pyrimidines with pde v inhibitory effect for the treatment of erectile dysfunction

Publications (2)

Publication Number Publication Date
AU2001237379A1 true AU2001237379A1 (en) 2001-11-22
AU2001237379B2 AU2001237379B2 (en) 2005-05-05

Family

ID=7633516

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001237379A Ceased AU2001237379B2 (en) 2000-03-03 2001-02-13 Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction
AU3737901A Pending AU3737901A (en) 2000-03-03 2001-02-13 Use of pde v inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3737901A Pending AU3737901A (en) 2000-03-03 2001-02-13 Use of pde v inhibitors

Country Status (13)

Country Link
US (1) US20030022906A1 (en)
EP (1) EP1259229B1 (en)
JP (1) JP2004504269A (en)
AT (1) ATE297719T1 (en)
AU (2) AU2001237379B2 (en)
CA (1) CA2401585A1 (en)
CO (1) CO5210873A1 (en)
DE (2) DE10010612A1 (en)
ES (1) ES2241798T3 (en)
MX (1) MXPA02008571A (en)
PE (1) PE20011165A1 (en)
PT (1) PT1259229E (en)
WO (1) WO2001064192A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031585A1 (en) * 2000-06-29 2002-01-10 Merck Patent Gmbh 2-aminoalkyl-thieno [2,3-d] pyrimidine
JPWO2003035653A1 (en) * 2001-10-26 2005-02-10 日本曹達株式会社 Pyridothienopyrimidine compounds and salts thereof
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
CA2694009A1 (en) * 2007-07-26 2009-01-29 F. Hoffmann-La Roche Ag Dual modulators of 5-ht2a and d3 receptors
CN104945412B (en) * 2015-05-26 2018-01-23 温州医科大学 Tetrahydro benzo thieno [2,3 d] aminopyridine derivative for FGFR1 and preparation method and application

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132993A0 (en) * 1997-05-29 2001-03-19 Mochida Pharm Co Ltd Therapeutic agent for erection failure
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
DE19819023A1 (en) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidines
US6265420B1 (en) * 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
EP1112069A2 (en) * 1998-08-25 2001-07-04 Alpharma-Isis GmbH & Co. KG Medicament utilization and combination
MXPA00003997A (en) * 1999-04-30 2002-03-08 Lilly Icos Llc Articles of manufacture.
DE19928146A1 (en) * 1999-06-19 2000-12-21 Merck Patent Gmbh New 3-benzylamino-benzothienopyrimidine derivatives inhibit phosphodiesterase V and are useful for treating cardiac insufficiency and impotence
US6476037B1 (en) * 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism

Similar Documents

Publication Publication Date Title
AU4583899A (en) Nasal administration of sildenafil for the treatment of erectile dysfunction
IL138907A0 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
MXPA03002814A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases.
IL157320A0 (en) Rapid-onset medicament for the treatment of sexual dysfunction
IL222455A0 (en) Methods for the preparation, isolation and purification of epothilone b
NO20024364D0 (en) Use of pyrido [3,2-E] pyrazinones as inhibitors of phosphodiesterase 5 for the treatment of erectile dysfunction
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU2001274649A1 (en) Topical preparation of alprostadil for the treatment of erectile dysfunction
AU2002238106A1 (en) Melanocortin metallopeptides for treatment of sexual dysfunction
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
AU2001260834A1 (en) The treatment of herpes
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
AU2001237379A1 (en) Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction
AU2002246924A1 (en) Treatment of erectile dysfunction with rho-kinase inhibitors
AU7652400A (en) Novel combination for the treatment of sexual dysfunction
AU2001278680A1 (en) Erectile dysfunction remedies containing prostaglandin derivatives as the activeingredient
AU2001284125A1 (en) Medicine for fighting against sexual dysfunction
ZA200203069B (en) Peptides for treatment of erectile dysfunction.
AU2000275972A1 (en) Pde iii inhibitors for treating sexual dysfunction
EP1395593A4 (en) Novel pyrazolopyrimidinethione derivatives. preparation methods thereof and their use as therapeutics for erectile dysfunction
AU2001292500A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
AU2001250530A1 (en) Treatment of conditions of the central nervous system using mycobacteria